Aptose Biosciences (NASDAQ:APTO) Given Overweight Rating at Piper Sandler

Aptose Biosciences (NASDAQ:APTOGet Free Report) (TSE:APS)‘s stock had its “overweight” rating restated by analysts at Piper Sandler in a research note issued on Wednesday, Benzinga reports. They currently have a $5.00 target price on the biotechnology company’s stock. Piper Sandler’s price objective points to a potential upside of 233.18% from the company’s previous close.

APTO has been the subject of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 target price on shares of Aptose Biosciences in a research note on Wednesday, March 27th. StockNews.com raised shares of Aptose Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, March 28th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Aptose Biosciences has an average rating of “Moderate Buy” and a consensus price target of $19.80.

Get Our Latest Stock Report on Aptose Biosciences

Aptose Biosciences Stock Performance

Shares of NASDAQ APTO traded down $0.08 during trading on Wednesday, reaching $1.50. The company had a trading volume of 45,034 shares, compared to its average volume of 91,847. Aptose Biosciences has a 52 week low of $1.36 and a 52 week high of $9.60. The stock has a market cap of $23.59 million, a PE ratio of -0.19 and a beta of 1.29. The business’s 50 day moving average price is $1.79 and its 200-day moving average price is $2.30.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC boosted its holdings in shares of Aptose Biosciences by 256.6% in the fourth quarter. Citadel Advisors LLC now owns 61,875 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 44,522 shares during the period. Texas Capital Bank Wealth Management Services Inc acquired a new position in shares of Aptose Biosciences in the fourth quarter valued at approximately $32,000. Annandale Capital LLC boosted its holdings in shares of Aptose Biosciences by 40.0% in the third quarter. Annandale Capital LLC now owns 74,666 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 21,334 shares during the period. Sigma Planning Corp acquired a new position in shares of Aptose Biosciences in the third quarter valued at approximately $408,000. Finally, DRW Securities LLC acquired a new position in shares of Aptose Biosciences in the fourth quarter valued at approximately $5,158,000. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

(Get Free Report)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Featured Stories

Analyst Recommendations for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.